期刊文献+

34βE12、Galectin-3及HBME-1在甲状腺良、恶性结节中的表达差异及临床诊断价值 被引量:6

Expression and diagnostic value of 34βE12,Galectin-3 and HBME-1 in thvroid nodules
下载PDF
导出
摘要 目的分析甲状腺良恶性结节中34βE12、Galectin-3及HBME-1的表达状况,并探讨其在鉴别甲状腺乳头状癌(papillary thyroid carcinoma,PTC)与甲状腺良性结节中的临床价值。方法采用免疫组化En Vision TM两步法检测352例患者中34βE12、Galectin-3及HBME-1的表达水平,分析这3个蛋白标记物与PTC临床病理特征的相关性,利用ROC曲线评估其鉴别诊断价值。结果 34βE12、Galectin-3及HBME-1在PTC病灶中的阳性率均显著高于甲状腺良性结节中的表达水平,且这3个蛋白标记物在PTC不同性别、年龄、病灶数目、肿瘤大小、包膜是否突破、有无淋巴结转移以及TNM分期中的表达差异均无统计学意义(P均>0.05)。34βE12、Galectin-3及HBME-1对鉴别PTC与甲状腺良性疾病中的ROC曲线下面积(AUC)分别为0.936、0.915、0.898,灵敏度分别为94.3%、95.5%、91.1%,特异度分别为81.1%、71.7%、83.0%,准确度分别为90.3%、88.4%、88.6%。结论 34βE12、Galectin-3及HBME-1在甲状腺良恶性结节中的表达存在统计学差异,并且与PTC的临床病理特征无关,对鉴别甲状腺良恶性结节的性质具有重要的临床辅助价值。 OBJECTIVE To study the expressions of 34βE12,Galectin-3 and HBME-1 in thyroid nodules,and to explore its diagnostic value for papillary thyroid carcinoma(PTC).METHODS En Vision-(TM) immunohistochemical technique was used to detect the expression of 34βE12,Galectin-3 and HBME-1 in 352 thyroid lesions.The correlation between the expressions of the 3 protein markers and clinicopathological characteristics was evaluated.The receiver operating characteristic area under the curve(ROC-AUC) and their index for diagnosis evaluation were also calculated.RESULTS The positive rates of 34βE12,Galectin-3 and HBME-1 in 246 PTC lesions were significantly higher than those in benign nodules(P〈0.001).There was no relationship between the expression of the 3 protein markers and clinicopathological characteristics(eg.gender,age,numbers of lesions,tumor size,capsular invasion,lymph node metastasis,TNM staging).The ROC-AUC of 34βE12,Galectin-3 and HBME-1 for diagnosis of PTC was 0.936,0.915 and 0.898 respectively.The sensitivity of 34βE12,Galectin-3 and HBME-1 for diagnosis of PTC was 94.3%,95.5%and 91.1%respectively,while the specificity was 81.1%,71.7%and83.0%respectively,and the diagnostic accuracy rate was90.3%,88.4%and 88.6%respectively.CONCLUSION The expressions of 34βE12,Galectin-3 and HBME-1 are statistically different between PTC and benign lesions,but no associations are found with clinicopathological characteristics,indicating the three protein markers have important diagnostic value for PTC.
出处 《中国耳鼻咽喉头颈外科》 CSCD 2016年第2期88-92,共5页 Chinese Archives of Otolaryngology-Head and Neck Surgery
基金 浙江省杭州市重大科技创新专项项目(20131813A08) 浙江省杭州市医药卫生科技计划项目(2012B004 2014A02)联合资助
关键词 甲状腺结节 甲状腺肿瘤 诊断 鉴别 34ΒE12 GALECTIN-3 HBME-1 Thyroid Nodule Thyroid Neoplasms Diagnosis Differential 34βE12 Galectin-3 HBME-1
  • 相关文献

参考文献18

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10-29.
  • 2边学.甲状腺乳头状癌与转移淋巴结组织蛋白质组学差异表达分析[J].中国耳鼻咽喉头颈外科,2011,18(7):363-366. 被引量:3
  • 3Tan A, Etit D, Bayol U, et al. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-l, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol, 2011, 15: 108-116.
  • 4Hashimoto K, Morimoto A, Kato M, et al. Immunocytochemical analysis for differential diagnosis of thyroid lesions using liquid-based cytology. Nagoya J Med Sci, 2011, 73: 15-24.
  • 5Abd-E1 Raouf SM, lbrahim TR. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derivedthyroid nodules. Pathol Res Pract, 2014, 210: 971-978.
  • 6Cui W, Sang W, Zheng S, et al. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules. Clin Lab, 2012, 58: 673- 680.
  • 7Ohta M, Ookoshi T, Naiki H, et al. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma. Pathol Int, 2015, 65: 119-125.
  • 8Ronald AD, Ricardo VL, Philipp UH, et al. World Health Organization classification of tumors pathology and genetics of tumors of endocrine organs. United Kingdom and Europe: Oxford University Press, 2004: 57-66.
  • 9Ozolins A, Narbuts Z, Strumfa 1, et al. Immunohistochemical expression of HBMEq, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas), 2012, 48: 507- 5014.
  • 10Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 2006, 295: 2164-2167.

二级参考文献32

  • 1何涛,宋凤卿,李海霄.大鼠十二导同步心电图与六导同步肢导联心电图的对比分析[J].广西医科大学学报,2009,26(6):871-872. 被引量:2
  • 2刘艳伟,刘水平,成建定,陈玉川.大鼠心肌缺血再灌注模型的改进及心电图判断指标[J].实用儿科临床杂志,2007,22(7):525-527. 被引量:37
  • 3乐杰,沈铿.妇产科学[M].第7版.北京:人民卫生出版社,2005:254.
  • 4Noguchi M, Kinami S, Kinoshita K. et al. Risk of bilateral cervical lymph node metastases in papillary thyroid cancer. J SurgOncol, 1993, 52: 155-159.
  • 5Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab, 1997, 82: 1638-1641.
  • 6Besic N, Pilko G, Petric R, et al. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol, 2008, 97: 221-225.
  • 7White ML, Doherty GM. Level VI lymph node dissection for papillary thyroid cancer. Minerva Chir, 2007, 62: 383-393.
  • 8Hamatani K, Eguchi H, Ito R, et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res, 2008, 68: 7176-7182.
  • 9Henderson YC, ShellenbergerTD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res, 2009, 15: 485-491.
  • 10Carmeci C, Thompson DA, Kuang WW, et al. Moesin expression is associated with the estrogen receptor-negative breast cancerphenotype. Surgery, 1998, 124: 211-217. T.

共引文献23

同被引文献35

  • 1Jendrzejewski J, He tt. Radomska HS, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinonla through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA, 2012, 109: 8646-865I.
  • 2Huang MD. Chen WM, Qi FZ, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell proliferation by epigenetic silencing of KLF2. J Hematol Oncol. 2015, 8: 50-64.
  • 3Li J. Li P, Zhao W, et al. Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma. Cancer Cell Int. 2015, 15: 48-56.
  • 4Shen X, Xie B, Ma Z, et al. Identification of novel long non- coding RNAs in triple-negative breast cancer. Oncotarget, 2015, 6: 21730-21739.
  • 5Xing M+ Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA, 2013, 309: 1493-1501.
  • 6Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014, 159: 676-690.
  • 7Lan X, Zhang H, Wang Z, et al. Genome-wide analysis of long noncoding RNA expression profile in papillary thyroid carcinoma. Gene, 2015, 569:109-117.
  • 8Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 2013. 13: 184-199.
  • 9Wang Y, Guo Q, Zhao Y, et al. BRAF-activated long non- coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett, 2014. 8: 1947-1952.
  • 10Wang C, Yan G, Zhang Y, et al. Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting ofRacl. Neoplasma, 2015.62: 541-549.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部